WUXIDAR4
LIVE

Serial Number

90031603

Owner

WUXI BIOLOGICS CO., LTD.

Attorney

Michael T. Smith

First Use Date

Sep 25, 2020

Filing Date

Jul 1, 2020

Add to watchlist:

No watchlists yet
View on USPTO

WUXIDAR4 Trademark

Serial Number: 90031603 • Registration: 6512549

WUXIDAR4 is a trademark filed by WUXI BIOLOGICS CO., LTD. on July 1, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

WUXI BIOLOGICS CO., LTD. (17 trademarks)

108 MEILIANG ROAD,

Entity Type: 03

WUXI XDC SINGAPORE PRIVATE LIMITED (3 trademarks)

100 TRAS STREET #16-01
100 AM SINGAPORE 079027 , SG

Entity Type: 24

Trademark Details

Filing Date

July 1, 2020

Registration Date

October 5, 2021

First Use Anywhere

September 25, 2020

First Use in Commerce

September 25, 2020

Published for Opposition

January 19, 2021

Goods & Services

pharmaceutical preparations for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; drugs for medical purposes, namely, anticancer drugs; biological preparations for medical purposes for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; medicines for human purposes for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Biochemical medicines for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Antibody drug for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; multispecific antibody for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; multispecific antibody format for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; medicines for veterinary purposes for treatment of canine disease; biological preparations for veterinary purposes for treatment of canine disease

Product development for others; pharmaceutical drug development services; scientific research and development; pharmaceutical research; research and development of new products; Consulting services in the field of pharmaceutical technology development; Biochemical research and analysis; Biomedical research services; development of pharmaceutical preparations and medicines; Research and development of antibodies

Filing History

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 5, 2023 ASGN
REGISTERED-PRINCIPAL REGISTER
Oct 5, 2021 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Sep 1, 2021 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Aug 31, 2021 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Aug 27, 2021 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 26, 2021 AITU
USE AMENDMENT FILED
Aug 24, 2021 IUAF
TEAS STATEMENT OF USE RECEIVED
Aug 24, 2021 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 16, 2021 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 19, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jan 19, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 30, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 11, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 9, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 8, 2020 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Dec 8, 2020 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Nov 28, 2020 GNFN
FINAL REFUSAL E-MAILED
Nov 28, 2020 GNFR
FINAL REFUSAL WRITTEN
Nov 28, 2020 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 21, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 20, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 20, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 25, 2020 GNRN
NON-FINAL ACTION E-MAILED
Sep 25, 2020 GNRT
NON-FINAL ACTION WRITTEN
Sep 25, 2020 CNRT
ASSIGNED TO EXAMINER
Sep 13, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 29, 2020 NWOS
NEW APPLICATION ENTERED
Jul 4, 2020 NWAP